# Nuvalent

Nuvalent is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** nuvalent.com
- **LinkedIn:** https://www.linkedin.com/company/nuvalent-inc

## Regulatory record

- **Reports private funds:** No

## About

#PreciselyTargetedTherapies for patients with cancer | Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

## Sectors

- Healthcare Services

## People

- James Porter — Chief Executive Officer
- Alexandra Balcom — Chief Financial Officer

## Questions

### Who runs investment decisions at Nuvalent?

As an operating biotech company, Nuvalent deploys capital through management-led R&D decisions rather than an investment committee. CEO James Porter heads strategic allocation, while the board of directors, which includes representatives from Deerfield Management, reviews major financial decisions. There is no separate CIO or investment team — resource allocation functions through standard public-company budgeting tied to clinical milestones.

### What investment stages does Nuvalent target?

Nuvalent does not invest in external companies and does not participate in funding rounds. As a drug developer, it is itself a portfolio company for healthcare investors, having gone through Series A financing before its 2021 IPO. Institutional allocators interact with Nuvalent only by buying or selling its publicly listed shares or by holding it as a portfolio position.

### Which cancers does Nuvalent explicitly avoid?

Nuvalent has not publicly indicated plans to pursue hematological malignancies, solid tumors outside of kinase-defined subtypes, or immuno-oncology approaches. The pipeline focuses exclusively on solid tumors driven by kinase fusions or mutations where a small-molecule inhibitor can be rationally designed. This means common tumor types without a defined kinase dependency — such as prostate, pancreatic, or colorectal cancers that lack a clear targetable driver — are effectively excluded from the current research scope.

### How is Nuvalent related to Deerfield Management?

Deerfield Management was a founding investor in Nuvalent's 2017 Series A and has maintained a board seat and significant equity position since inception. Deerfield's initial involvement provided the seed funding that established the company's lab operations and discovery platform. The two firms are otherwise independent: Nuvalent is a publicly traded drug developer, Deerfield is a private healthcare investment firm, and Nuvalent makes no investment allocations to Deerfield funds.

### What is Nuvalent's known posture on co-investments alongside external biotech partners?

Nuvalent has not entered any clinical co-development partnerships as of early 2025. While many peer oncology companies pursue shared-risk development deals with large pharmaceutical firms, Nuvalent has retained full global rights to its pipeline candidates. This go-it-alone posture means external firms cannot co-invest in Nuvalent's clinical programs directly; exposure is available only through public equity markets.

## Related profiles

- [Ormat Technologies](https://altss.com/profile/ormat-technologies-inc)
- [WINNERS, INC.](https://altss.com/profile/winners-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nuvalent-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology